New England Journal of Medicine publishes results from pivotal study of WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome
2019-08-07 · Ionis Pharmaceuticals · original ionis.com ↗
Mean triglyceride levels decreased 77% in volanesorsen-treated patients versus an 18% increase in patients in placebo group Akcea launching WAYLIVRA in the European Union BOSTON and CARLSBAD, Calif, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue ofThe New England Journal of Medicine (NEJM). The manuscript is titled “Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.”
The release as fetched from its publisher. ionis.com ↗